Cybin-backed HELP trial eyes HLP003 Phase III data in Q4 2026
A late-stage mental health pipeline includes HLP003 in Phase III for adjunctive MDD, with top-line data expected in Q4 2026 and an NDA filing targeted for 2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.